首页> 外文期刊>Chemical and Pharmaceutical Bulletin >Prediction of compatibility between ozagrel sodium preparation for injection and calcium on the basis of the solubility product
【24h】

Prediction of compatibility between ozagrel sodium preparation for injection and calcium on the basis of the solubility product

机译:基于溶解度产物预测奥扎格雷钠注射液与钙的相容性

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of the study was to evaluate the compatibility of ozagrel sodium solution and calcium-containing transfusions using solubility product constants. We calculated the solubility product constant of mixtures of ozagrel sodium and calcium chloride and evaluated the compatibility of ozagrel sodium solution (both the original and generic products) with calcium chloride solution using a light obscuration particle counter. Various volumes of ozagrel solution were added to the calcium solutions to make final ozagrel concentrations of 0, 0.8, 1.6, 2.0, 2.4, 3.2 and 4.0 mmol/L. The solutions were gently agitated and stored at 25 and 40°C. The ozagrel concentration, calcium ion concentration and number of microparticles were measured. The solubility product constants obtained were 11.89×10-~9 mol~3/L~3 (at 25°C) and 7.82×10-~9 mol~3/L~3 (40°C). The number of insoluble microparticles was significantly increased when the ionic product was larger than the solubility product constant. In all ozagrel sodium products, the number of insoluble microparticles was within the allowable range according to the Japanese Pharmacopoeia. These results suggest that mixing ozagrel sodium with calcium-containing products is safe and without appreciable risk of incompatibility under clinical conditions.
机译:该研究的目的是使用溶解度乘积常数评估奥扎格雷钠溶液和含钙输血的相容性。我们计算了奥扎格雷钠和氯化钙混合物的溶解度常数,并使用光遮蔽粒子计数器评估了奥扎格雷钠溶液(原始产品和通用产品)与氯化钙溶液的相容性。将各种体积的奥扎格雷溶液添加到钙溶液中,使奥扎格雷的最终浓度为0、0.8、1.6、2.0、2.4、3.2和4.0 mmol / L。轻轻搅拌溶液并在25和40℃下保存。测量奥扎格雷浓度,钙离子浓度和微粒数。获得的溶解度产物常数为11.89×10-〜9 mol〜3 / L〜3(在25°C)和7.82×10-〜9 mol〜3 / L〜3(40°C)。当离子产物大于溶解度产物常数时,不溶性微粒的数目显着增加。在所有奥扎格雷钠产品中,根据日本药典,不溶性微粒的数量在允许范围内。这些结果表明,将奥扎格雷钠与含钙产品混合是安全的,并且在临床条件下不存在明显的不相容风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号